Clinical Information Search
Search Results for "diabetes_articles"
- Online Learning Center (0)
- Policy Library (103)
- Performance Measures (0)
- Annals of Internal Medicine (1952)
- Annals of Internal Medicine: Clinical Cases (143)
- IM Matters (6)
- ACP Hospitalist (42)
- ACP Diabetes Monthly (58)
- ACP Gastroenterology Monthly (4)
Sorry, no results were found for "diabetes_articles" in Online Learning Center.
Sorry, no results were found for "diabetes_articles" in Performance Measures.
Displaying 231 - 240 of 1952 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Source Citation Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309-20. 31475798 Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169-80. 31484629
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Source Citation Wiviott SD, Raz I, Bonaca MP. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. 30415602 Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:606-17. 31196815
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
Source Citation Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes—15-year follow-up. N Engl J Med. 2019;380:2215-24. 31167051
In high-risk type 1 diabetes, insulin pumps with suspend-before-low technology reduced hypoglycemic events
Source Citation Bosi E, Choudhary P, de Valk HW, et al; SMILE Study Group. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:462-72. 31047902
In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c
Source Citation Pratley R, Amod A, Hoff ST, et al; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39-50. 31186120
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events
Source Citation Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019. [Epub ahead of print]. 31185157
In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes
Source Citation Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30. 31189511
In type 2 diabetes, a primary care–led weight management program increased weight loss and diabetes remission at 2 years
Source Citation Lean ME, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7:344-55. 30852132
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
Source Citation Rosenstock J, Allison D, Birkenfeld AL, et al; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA. 2019;321:1466-80. 30903796
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Source Citation Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. 30990260